Search results
Oracle Alpha Inc. Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 24 hours agoOracle Alpha Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report ...
Westwood Holdings Group Inc. Has $11.22 Million Stock Position in Regeneron Pharmaceuticals, Inc....
ETF DAILY NEWS· 7 days agoWestwood Holdings Group Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.4% ...
...Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN - Regeneron...
Benzinga· 17 hours agoNEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past...
Simply Wall St. via Yahoo Finance· 2 days agoBut on a lighter note, a good company can see its share price rise well over 100%. Long term ...
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
Zacks via Yahoo Finance· 4 days agoRegeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced that the FDA has approved a...
RBC lifts Regeneron stock PT to $1,229 on higher sales estimetes of Dupixent By Investing.com
Investing.com· 4 days agoOn Wednesday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw an increase in its price target to...
Analyst Report: Regeneron Pharmaceuticals, Inc.
Morningstar Research via Yahoo Finance· 1 day agoRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products ...
REGN, CI, BSX: Which “Strong Buy” Healthcare Stock Is the Best Bet?
TipRanks via Yahoo Finance· 3 days agoFor value investors looking to take a “break” from the euphoric technology stocks, many of which may...
...Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market - Regeneron...
Benzinga· 3 days agoAnalyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Top Stock Reports for Procter & Gamble, ServiceNow & Lockheed Martin
Zacks via Yahoo Finance· 4 days agoToday's Research Daily features new research reports on 16 major stocks, including The Procter &...